Busulfanum
Testicular Non-Seminomatous Germ Cell Tumor
Explore 4 assets in Testicular Non-Seminomatous Germ Cell Tumor →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Testicular Non-Seminomatous Germ Cell Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Busulfanum (this asset) | City of Hope Medical Center | P1 | CC · 47 |
| Palbociclib | Abramson Cancer Center at Penn Medicine | P2 | B |
| Cabozantinib | Jennifer King | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Etoposide | Nabil Adra | P2 | CCC |
| Pembrolizumab | Nasser Hanna, M.D. | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nogitecan | City of Hope Medical Center | P1 | CC |
| Nivestim | City of Hope Medical Center | P1 | CC |
+1 more in the Testicular Non-Seminomatous Germ Cell Tumor cohort
Other indications for Busulfanum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 76 |
| Graft Versus Host Disease | — | P4 | BBB · 74 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P3 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Busulfanum in Testicular Non-Seminomatous Germ Cell Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/busulfanum-testicular-non-seminomatous-germ-cell-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →